Navigation Links
Boehringer Ingelheim Announces Equine Research Awards
Date:12/3/2012

ST. JOSEPH, Mo., Dec. 3, 2012 /PRNewswire/ -- Researchers at two universities will be studying equine pigeon fever (Corynebacterium pseudotuberculosis) as recipients of the 2012 Advancement of Equine Research Awards, sponsored by Boehringer Ingelheim Vetmedica, Inc. (BIVI).

(Logo:  http://photos.prnewswire.com/prnh/20120925/CG80722LOGO)

Proposals by Roberta R. Pollock, Ph.D., professor of biology at Occidental College, and Allison J. Stewart, BVSc, professor of equine internal medicine at Auburn University, were selected by a panel of equine practitioners and university professors and researchers in veterinary medicine. Each award will provide $25,000 for 12-month research programs at each institution. The research awards were announced during the recent 2012 American Association of Equine Practitioners Annual Convention in Anaheim, Calif.

"The quality of equine research proposals this year was exceptional," says Steve Grubbs, DVM, PhD, DACVIM equine professional services, BIVI. "Although this is an academic award, the top priority is to identify projects that ultimately can improve the quality of life for horses and their owners."

Dr. Pollock will focus her efforts on combining equine disease infection studies with a mouse model for pigeon fever to identify and clone protective protein antigens from Corynebacterium pseudotuberculosis. Areas of research will include the pathophysiology of Corynebacterium pseudotuberculosis and development of an equine challenge model, and comparison of host immunity between infections resulting in internal infection and recurrent infection in recovered horses.

Dr. Stewart, assisted by graduate student Marta Barbra Recreo, will look into the transmission of Corynebacterium pseudotuberculosis in horses by houseflies. Like Dr. Pollock, she will focus on pathophysiology and a challenge model, as well as seasonality of Corynebacterium pseudotuberculosis infection and studies of insect vectors.

The topic for the 2013 awards will be announced next spring. Veterinarians, diagnosticians, and public and private researchers in the United States and Canada are eligible to submit proposals. Awards will be selected based on established criteria, including potential impact on the equine industry; originality and scientific quality; and probability of success in completing the yearlong studies.

"I am encouraged by the quality of the proposals submitted this year," Dr. Grubbs says. "BIVI is proud to take a leading role in helping provide equine health solutions, but we would not be nearly as successful without the ongoing research conducted by dedicated research and veterinary medical professionals around the country."

For more information and complete submission instructions, please visit www.equinediseaseresearch.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.


'/>"/>
SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
2. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
3. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
4. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
5. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
6. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
7. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
8. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
11. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ZIONA SCIENCE PARK , Israel ... company Kadimastem (TASE: KDST) announced today the signing of a memorandum ... between the companies. The synergy between the companies will assist in ... as a worldwide leader in innovative treatment for severe diseases in ... ...
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
(Date:12/7/2016)... The global  blood screening ... USD 3.9 billion by 2024, based on a ... growth of the market is attributed to the ... by the market players. Demand for blood screening ... rising awareness about transfusion-transmitted diseases, and technological developments ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back ... not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... the children of the world. , In exchange for generous donations, customers will receive ...
(Date:12/7/2016)... ... 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... Voice of America, declared on her radio program in November 2016 the need to ... these bullies attack leaders in corporate America, they are trying to take advantage of ...
(Date:12/7/2016)... Phoenix, Arizona (PRWEB) , ... December 07, 2016 , ... ... Juvederm®, Just in Time For The Holiday Party Season. Save Up To 33% Off ... and Laser Salon is providing the Phoenix Valley with Delightful Deals on ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers ... Plus substantially enhances the WellnessPro platform by expanding the treatment modalities available ...
Breaking Medicine News(10 mins):